CY1123637T1 - Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων - Google Patents
Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτωνInfo
- Publication number
- CY1123637T1 CY1123637T1 CY20201101194T CY201101194T CY1123637T1 CY 1123637 T1 CY1123637 T1 CY 1123637T1 CY 20201101194 T CY20201101194 T CY 20201101194T CY 201101194 T CY201101194 T CY 201101194T CY 1123637 T1 CY1123637 T1 CY 1123637T1
- Authority
- CY
- Cyprus
- Prior art keywords
- transfer inhibitors
- arginine methyl
- methyl transfer
- compounds
- arginine methyltransferase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Abstract
Στο κείμενο περιγράφονται ενώσεις του Τύπου (Ι), αποδεκτά από φαρμακευτική άποψη άλατα αυτών, και φαρμακευτικές συνθέσεις αυτών. Οι ενώσεις που περιγράφονται στο κείμενο είναι χρήσιμες για την αναστολή της ενεργότητας της μεθυλοτρανσφεράσης αργινίνης. Επίσης περιγράφονται μέθοδοι χρήσης των ενώσεων για την αγωγή διαταραχών μεσολαβούμενων από μεθυλοτρανσφεράση αργινίνης.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361781051P | 2013-03-14 | 2013-03-14 | |
US201361876034P | 2013-09-10 | 2013-09-10 | |
PCT/US2014/029710 WO2014153226A1 (en) | 2013-03-14 | 2014-03-14 | Arginine methyltransferase inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123637T1 true CY1123637T1 (el) | 2022-03-24 |
Family
ID=50483598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201101194T CY1123637T1 (el) | 2013-03-14 | 2020-12-17 | Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων |
Country Status (25)
Country | Link |
---|---|
US (4) | US9598374B2 (el) |
EP (1) | EP2970132B1 (el) |
JP (1) | JP6581076B2 (el) |
KR (2) | KR102028793B1 (el) |
CN (2) | CN105339351B (el) |
AU (2) | AU2014236146B2 (el) |
BR (1) | BR112015022785A2 (el) |
CA (1) | CA2903394C (el) |
CY (1) | CY1123637T1 (el) |
DK (1) | DK2970132T3 (el) |
EA (1) | EA030481B1 (el) |
ES (1) | ES2837034T3 (el) |
HK (1) | HK1219736A1 (el) |
HR (1) | HRP20202008T1 (el) |
HU (1) | HUE052926T2 (el) |
IL (2) | IL241368B (el) |
LT (1) | LT2970132T (el) |
MX (1) | MX2015012850A (el) |
PL (1) | PL2970132T3 (el) |
PT (1) | PT2970132T (el) |
RS (1) | RS61231B1 (el) |
SG (1) | SG11201506972PA (el) |
SI (1) | SI2970132T1 (el) |
WO (1) | WO2014153226A1 (el) |
ZA (1) | ZA201507441B (el) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
EP2935247B1 (en) | 2012-12-21 | 2019-08-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
CA2894126A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US20160031839A1 (en) | 2013-03-14 | 2016-02-04 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970133B1 (en) | 2013-03-14 | 2018-10-24 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
WO2014153214A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
JP2016518336A (ja) | 2013-03-14 | 2016-06-23 | エピザイム,インコーポレイティド | Prmt1阻害剤としてのピラゾール誘導体およびその使用 |
EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970135B1 (en) | 2013-03-14 | 2018-07-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
SG11201506972PA (en) | 2013-03-14 | 2015-10-29 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
US9776972B2 (en) | 2013-03-14 | 2017-10-03 | Epizyme Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
US9718816B2 (en) | 2013-03-15 | 2017-08-01 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof |
CA2903813C (en) | 2013-03-15 | 2023-08-29 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
US10653693B2 (en) | 2014-08-04 | 2020-05-19 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
WO2016044576A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
KR20190090822A (ko) * | 2016-12-01 | 2019-08-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 조합 요법 |
BR112019011388A2 (pt) * | 2016-12-01 | 2019-10-15 | Glaxosmithkline Ip Dev Ltd | terapia de combinação |
CN110225983A (zh) * | 2016-12-01 | 2019-09-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 治疗癌症的方法 |
CN111867584A (zh) * | 2018-03-01 | 2020-10-30 | 德州大学系统董事会 | 作为蛋白质精氨酸甲基转移酶的抑制剂的乙二胺-杂环衍生物 |
CN112469441A (zh) * | 2018-05-31 | 2021-03-09 | 葛兰素史克知识产权开发有限公司 | 用icos结合蛋白和精氨酸甲基转移酶抑制剂的组合疗法 |
WO2020182018A1 (zh) * | 2019-03-12 | 2020-09-17 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、其制备方法及用途 |
EP3947387A4 (en) * | 2019-03-25 | 2022-11-30 | California Institute Of Technology | PRMT5 INHIBITORS AND USES THEREOF |
WO2021023609A1 (en) * | 2019-08-02 | 2021-02-11 | Glaxosmithkline Intellectual Property Development Limited | Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor |
CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
KR102219251B1 (ko) | 2020-03-03 | 2021-02-22 | 김명수 | 전문가 추천 플랫폼을 제공하는 서버 및 그 운용방법 |
CN111481532B (zh) * | 2020-06-28 | 2020-09-22 | 南京中澳转化医学研究院有限公司 | 化合物28d在制备提高γ-珠蛋白表达量的药物中的应用 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH085859B2 (ja) | 1986-07-01 | 1996-01-24 | 日本バイエルアグロケム株式会社 | 新規アルキレンジアミン類 |
EP0352581A3 (de) | 1988-07-28 | 1990-07-04 | F. Hoffmann-La Roche Ag | Aethylendiaminmonoamid-Derivate |
US5204482A (en) | 1988-07-28 | 1993-04-20 | Hoffman-Laroche Inc. | Compounds for treating and preventing cognitive diseases and depression and methods of making same |
EP0796270A2 (en) | 1994-12-02 | 1997-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds for prevention and/or treatment of no-mediated diseases |
SE9902765D0 (sv) | 1999-07-21 | 1999-07-21 | Astra Pharma Prod | Novel compounds |
CN1331326A (zh) * | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸 |
US20020090627A1 (en) | 2000-10-05 | 2002-07-11 | Rachel Meyers | 27419, a novel human arginine-N-methyl transferase and uses thereof |
DE10149370A1 (de) | 2001-10-06 | 2003-04-10 | Merck Patent Gmbh | Pyrazolderivate |
NZ534830A (en) | 2002-03-13 | 2005-08-26 | Janssen Pharmaceutica Nv | Compounds with histone deacetylase HDAC inhibiting activity and oral bioavailability useful for treating proliferative diseases |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
AU2003288994A1 (en) | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
DE10315572A1 (de) | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazole |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
WO2004098634A2 (en) | 2003-04-30 | 2004-11-18 | Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health | Protein arginine n-methyltransferase 2 (prmt-2) |
US20050032794A1 (en) | 2003-08-05 | 2005-02-10 | Padia Janak K. | Diamine derivatives of quinone and uses thereof |
DE102004008807A1 (de) | 2004-02-20 | 2005-09-08 | Bayer Cropscience Ag | Pyrazolopyrimidine |
SI1725537T1 (sl) | 2004-03-15 | 2011-11-30 | Janssen Pharmaceutica Nv | Nove spojine kot modulatorji opioidnih receptorjev |
ME01309B (me) | 2004-08-26 | 2013-12-20 | Pfizer | Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza |
WO2006025832A1 (en) | 2004-08-31 | 2006-03-09 | University Of North Carolina At Chapel Hill | Dot1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
JP2008515950A (ja) | 2004-10-13 | 2008-05-15 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 泌尿器系障害の処置用の冷メントール受容体−1(cmr−1)アンタゴニストとしての4−置換ベンジルオキシ−フェニルメチルアミド誘導体 |
WO2006063356A1 (en) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation of epigenetic control of gene expression |
US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
BRPI0606455A (pt) | 2005-01-21 | 2008-03-11 | Astex Therapeutics Ltd | compostos farmacêuticos |
WO2006113458A1 (en) | 2005-04-15 | 2006-10-26 | Bristol-Myers Squibb Company | Heterocyclic inhibitors of protein arginine methyl transferases |
US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
SG140147A1 (en) | 2005-08-19 | 2008-03-28 | Aventis Pharma Inc | Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof |
EP1985620A4 (en) | 2006-02-07 | 2012-08-15 | Taisho Pharmaceutical Co Ltd | COMPOUND 10a-AZALIDE |
WO2007149782A2 (en) | 2006-06-23 | 2007-12-27 | University Of Medicine And Dentistry Of New Jersey | Selective inhibitors for transferases |
EP2035436B1 (en) | 2006-06-26 | 2011-05-25 | UCB Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
AU2007273057A1 (en) * | 2006-07-12 | 2008-01-17 | Merck Sharp & Dohme Corp. | Substituted pyrazoles as ghrelin receptor antagonists |
CN101511802A (zh) | 2006-09-13 | 2009-08-19 | 阿斯利康(瑞典)有限公司 | 螺唑烷酮化合物及其作为代谢型谷氨酸受体增效剂的用途 |
NZ575689A (en) | 2006-09-15 | 2011-12-22 | Celgene Corp | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
US20080312298A1 (en) | 2007-04-11 | 2008-12-18 | Kenneth William Foreman | Methods for Identification of Modulators of Carm1 Methyl Transferase Activity |
US20090062286A1 (en) | 2007-05-04 | 2009-03-05 | Kenneth William Foreman | Crystal Structure of SMYD3 Protein |
US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
US8133904B2 (en) | 2007-09-07 | 2012-03-13 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating obesity |
EP2226315A4 (en) | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-AMINOQUINAZOLINE DERIVATIVE |
JP2009179616A (ja) | 2008-01-31 | 2009-08-13 | Kowa Co | 3−ナフチルピラゾール化合物 |
ES2557281T3 (es) | 2008-02-29 | 2016-01-25 | Evotec Ag | Compuestos amida, composiciones y usos de los mismos |
WO2009126537A1 (en) | 2008-04-07 | 2009-10-15 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an hmt inhibitor |
US8512944B2 (en) | 2008-08-27 | 2013-08-20 | Oncotherapy Science, Inc. | PRMT1 for target genes of cancer therapy and diagnosis |
WO2010034737A1 (en) | 2008-09-24 | 2010-04-01 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
US8323918B2 (en) | 2008-12-12 | 2012-12-04 | University Of South Carolina | Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases |
WO2010094009A2 (en) | 2009-02-13 | 2010-08-19 | Children's Hospital Medical Center | Methods and compositions for the treatment of ras associated disorders |
US20130345268A1 (en) | 2009-02-13 | 2013-12-26 | The Trustees Of Dartmouth College | Methods and Compositions for the Treatment of RAS Associated Disorders |
EP2221053A1 (de) | 2009-02-20 | 2010-08-25 | Albert-Ludwigs-Universität Freiburg | Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen |
RU2011141121A (ru) * | 2009-03-11 | 2013-04-20 | Окленд Юнисервисиз Лимитед | Пролекарственные формы ингибиторов киназ и их применение в терапии |
IN2012DN00352A (el) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
US20110021362A1 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
US9044432B2 (en) | 2009-12-22 | 2015-06-02 | Ohio State Innovation Foundation | Compositions and methods for cancer detection and treatment |
WO2011082098A1 (en) | 2009-12-30 | 2011-07-07 | The Rockefeller University | Lysine and arginine methyltransferase inhibitors for treating cancer |
WO2011096210A1 (en) | 2010-02-03 | 2011-08-11 | Oncotherapy Science, Inc. | Prmt1 and prmt6 for target genes of cancer therapy and diagnosis |
EP2531598A4 (en) | 2010-02-03 | 2013-05-22 | Oncotherapy Science Inc | WHSC1 AND WHSC1L1 FOR TARGET GENES TO CANCER THERAPY AND DIAGNOSIS |
US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
JP5864545B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | インドール |
US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
KR102061353B1 (ko) | 2010-09-10 | 2020-01-02 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
WO2012060760A1 (en) | 2010-11-05 | 2012-05-10 | Fujirebio Diagnostics Ab | Molecular marker for cancer |
WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
ES2607064T3 (es) | 2010-12-01 | 2017-03-29 | Glaxosmithkline Llc | Indoles |
WO2012082436A2 (en) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
BR112013013659B8 (pt) | 2010-12-03 | 2024-02-27 | Epizyme Inc | Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia |
EP2646441B1 (en) | 2010-12-03 | 2015-12-02 | Epizyme, Inc. | Carbocycle-substituted purine and 7-deazapurine compounds |
KR20130124959A (ko) | 2010-12-03 | 2013-11-15 | 에피자임, 인코포레이티드 | 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법 |
AU2012223448B2 (en) | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
US9458174B2 (en) | 2012-05-23 | 2016-10-04 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof |
WO2014034750A1 (ja) | 2012-08-30 | 2014-03-06 | 国立大学法人 東京大学 | 内部寄生虫防除剤 |
EP3143994A1 (en) | 2012-08-30 | 2017-03-22 | The University of Tokyo | Endoparasite control agent and use thereof |
WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
EP2935247B1 (en) | 2012-12-21 | 2019-08-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2894126A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US9604930B2 (en) | 2012-12-21 | 2017-03-28 | Epizyme, Inc. | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof |
WO2014100764A2 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Methods of inhibiting prmt5 |
EP2970135B1 (en) | 2013-03-14 | 2018-07-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US9776972B2 (en) | 2013-03-14 | 2017-10-03 | Epizyme Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
US20160031839A1 (en) | 2013-03-14 | 2016-02-04 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
SG11201506972PA (en) | 2013-03-14 | 2015-10-29 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
JP2016518336A (ja) | 2013-03-14 | 2016-06-23 | エピザイム,インコーポレイティド | Prmt1阻害剤としてのピラゾール誘導体およびその使用 |
EP2970133B1 (en) | 2013-03-14 | 2018-10-24 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153214A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
CA2903813C (en) | 2013-03-15 | 2023-08-29 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
US9718816B2 (en) | 2013-03-15 | 2017-08-01 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof |
US20170210751A1 (en) | 2014-06-25 | 2017-07-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
EP3160477A4 (en) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US10653693B2 (en) | 2014-08-04 | 2020-05-19 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
WO2016044641A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
US20170291905A1 (en) | 2014-09-17 | 2017-10-12 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US20170305922A1 (en) | 2014-09-17 | 2017-10-26 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
WO2016044585A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP3200588A4 (en) | 2014-09-17 | 2018-04-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US20170283440A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
WO2016044576A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
JP2017527594A (ja) | 2014-09-17 | 2017-09-21 | エピザイム,インコーポレイティド | コアクチベーター関連アルギニンメチルトランスフェラーゼ1(carm1)阻害剤の塩、共結晶、非晶質形態、および結晶形態 |
WO2017136699A1 (en) | 2016-02-05 | 2017-08-10 | Epizyme, Inc | Arginine methyltransferase inhibitors and uses thereof |
US20190083482A1 (en) | 2017-09-18 | 2019-03-21 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
-
2014
- 2014-03-14 SG SG11201506972PA patent/SG11201506972PA/en unknown
- 2014-03-14 PL PL14717371T patent/PL2970132T3/pl unknown
- 2014-03-14 AU AU2014236146A patent/AU2014236146B2/en active Active
- 2014-03-14 US US14/775,794 patent/US9598374B2/en active Active
- 2014-03-14 RS RS20201553A patent/RS61231B1/sr unknown
- 2014-03-14 SI SI201431734T patent/SI2970132T1/sl unknown
- 2014-03-14 BR BR112015022785A patent/BR112015022785A2/pt not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/029710 patent/WO2014153226A1/en active Application Filing
- 2014-03-14 CN CN201480020631.8A patent/CN105339351B/zh active Active
- 2014-03-14 KR KR1020157029130A patent/KR102028793B1/ko active Application Filing
- 2014-03-14 KR KR1020197028270A patent/KR102158756B1/ko active IP Right Grant
- 2014-03-14 CA CA2903394A patent/CA2903394C/en active Active
- 2014-03-14 CN CN201811160725.1A patent/CN109265400B/zh active Active
- 2014-03-14 MX MX2015012850A patent/MX2015012850A/es unknown
- 2014-03-14 PT PT147173710T patent/PT2970132T/pt unknown
- 2014-03-14 EA EA201591531A patent/EA030481B1/ru unknown
- 2014-03-14 DK DK14717371.0T patent/DK2970132T3/da active
- 2014-03-14 EP EP14717371.0A patent/EP2970132B1/en active Active
- 2014-03-14 JP JP2016503202A patent/JP6581076B2/ja active Active
- 2014-03-14 ES ES14717371T patent/ES2837034T3/es active Active
- 2014-03-14 LT LTEP14717371.0T patent/LT2970132T/lt unknown
- 2014-03-14 HU HUE14717371A patent/HUE052926T2/hu unknown
-
2015
- 2015-09-09 IL IL241368A patent/IL241368B/en active IP Right Grant
- 2015-10-07 ZA ZA2015/07441A patent/ZA201507441B/en unknown
-
2016
- 2016-07-05 HK HK16107817.8A patent/HK1219736A1/zh unknown
-
2017
- 2017-02-01 US US15/421,699 patent/US10081603B2/en active Active
-
2018
- 2018-05-02 AU AU2018203056A patent/AU2018203056B2/en active Active
- 2018-09-07 US US16/124,936 patent/US10800743B2/en active Active
-
2019
- 2019-07-21 IL IL268189A patent/IL268189B/en unknown
-
2020
- 2020-08-27 US US17/004,881 patent/US11512053B2/en active Active
- 2020-12-15 HR HRP20202008TT patent/HRP20202008T1/hr unknown
- 2020-12-17 CY CY20201101194T patent/CY1123637T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123637T1 (el) | Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων | |
CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
CY1123756T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
WO2014153235A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
WO2014153100A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
BR112015022191A8 (pt) | compostos heteroarila e usos dos mesmos | |
WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
MY186547A (en) | 4?-fluoro-2?-methyl substituted nucleoside derivatives | |
EA201500628A1 (ru) | Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов | |
NI201500115A (es) | Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
BR112015029495A2 (pt) | compostos heterocíclicos como inibidores da via de sinalização hedgehog | |
PH12016500985A1 (en) | Use of benzimidazole-proline derivatives | |
UY35274A (es) | Compuestos y métodos para tratar infecciones bacterianas | |
EA201500931A1 (ru) | Производные пиридин-4-ила | |
CY1120133T1 (el) | Πυριδαζινονες ως αναστολεις ενζυμου daao | |
BR112017028549A2 (pt) | derivados de pirimidina como inibidores de btk e usos dos mesmos | |
BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
EA201500821A1 (ru) | Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов |